Skip to main content

Table 1 Clinical and functional characteristics of the entire IPF population, IPF patients with TT/TG genotype and with GG genotype

From: Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

 

Entire population (n = 88)

TT/TG genotype (n = 61)

GG genotype (n = 27)

p Value

Male, n (%)

71 (81)

49 (80)

22 (81)

0.99

Age at diagnosis, years

70 (44–84)

69 (44–84)

71(50–82)

0.30

Body mass index, kg/m2

26 (19–37)

26 (19–33)

27 (22–37)

0.49

Smoking history, pack years

10 (0–240)

10 (0–50)

30 (0–240)

0.0001

Current, n (%)

7 (8)

5 (8)

2 (7)

 

Former, n (%)

59 (67)

38 (62)

21 (78)

0.31

Nonsmokers, n (%)

22 (25)

18 (30)

4 (15)

 

Radiological diagnosis, n (%)

49 (56)

29 (48)

20 (74)

0.03

UIP

49

29

20

 

Probable UIP

31

24

7

0.03

Indeterminate UIP

8

8

0

 

FVC at baseline, L

2.60 (1.20–4.61)

2.68 (1.56–4.36)

2.32 (1.20–4.61)

0.02

FVC at baseline, %pred

77 (47–126)

78 (52–126)

68 (47–118)

0.05

TLC at baseline, %pred

73 (40–96)

73 (45–96)

73 (40–93)

0.37

DLCO at baseline, %pred

56 (7–93)

56 (7–89)

56 (28–93)

0.67

Gastroesophageal reflux, n (%)

32 (36)

23 (38)

9 (33)

0.69

Cardiovascular diseases, n (%)

63 (72)

44 (72)

19 (70)

0.86

Metabolic syndrome, n (%)

37 (42)

25 (41)

12 (44)

0.76

Pirfenidone treatment, n (%)

51 (58)

37 (61)

14 (52)

0.48

Nintedanib treatment, n (%)

37 (42)

24 (39)

13 (48)

0.48

FVC decline in the 1st year– mL

50 (-573–657)

84 (-573–657)

34 (-559–461)

0.54

FVC decline in the 1st year, %pred

1 (-29–21)

1 (-29–21)

0 (-12–16)

0.80

Stable in the 1st year, n (%)

63 (72)

45 (74)

18 (67)

0.60

Progressors in the 1st year, n (%)

25 (28)

16 (26)

9 (33)

 

RF on exercise, months

19 (0–89)

21 (0–89)

16 (0–44)

0.13

RF at rest, months

27 (0–110)

31 (5–110)

24 (0–59)

0.04

Nausea or vomiting, n (%)

15 (17)

13 (21)

2 (7)

0.10

Diarrhea, n (%)

16 (18)

12 (20)

4 (15)

0.58

Weight loss, n (%)

25 (28)

19 (31)

6 (22)

0.39

Increase in AST, ALT, n (%)

2 (2)

2 (3)

0 (0)

0.34

Acute exacerbations

5 (6)

3 (5)

2 (7)

0.56

Lung transplant, n (%)

5 (6)

4 (6)

1 (4)

0.17

Death, n (%)

27 (31)

15 (25)

12 (44)

0.06

  1. FVC  forced vital capacity, TLC total lung capacity, DLCO lung diffusion carbon oxide, RF respiratory failure, AST aspartate aminotransferase, ALT alanine aminostransferase. Values are expressed as numbers and (%) or median and ranges as appropriate. Negative values mean improvement of FVC. To compare demographic data and baseline clinical characteristics between TT/GT genotype and GG genotype, Chi square test and Fisher t test (n < 5) for categorical variables and Mann–Whitney U test for continuous variables were used. P-values < 0.05 were considered statistically significant (bold values)
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us